145 related articles for article (PubMed ID: 34497271)
1. Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease.
Lokugamage N; Chowdhury IH; Biediger RJ; Market RV; Khounlo S; Warier ND; Hwang SA; Actor JK; Woodside DG; Marathi U; Vanderslice P; Garg NJ
NPJ Vaccines; 2021 Sep; 6(1):114. PubMed ID: 34497271
[TBL] [Abstract][Full Text] [Related]
2.
Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
Front Immunol; 2019; 10():1456. PubMed ID: 31293599
[No Abstract] [Full Text] [Related]
3. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
Chowdhury IH; Lokugamage N; Garg NJ
Front Immunol; 2020; 11():595039. PubMed ID: 33414785
[TBL] [Abstract][Full Text] [Related]
4. A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
PLoS Pathog; 2015 May; 11(5):e1004828. PubMed ID: 25951312
[TBL] [Abstract][Full Text] [Related]
5. Antigen-Based Nano-Immunotherapy Controls Parasite Persistence, Inflammatory and Oxidative Stress, and Cardiac Fibrosis, the Hallmarks of Chronic Chagas Cardiomyopathy, in A Mouse Model of
Lokugamage N; Choudhuri S; Davies C; Chowdhury IH; Garg NJ
Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32098116
[TBL] [Abstract][Full Text] [Related]
6. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS
Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671
[TBL] [Abstract][Full Text] [Related]
8. Subunit nanovaccine elicited T cell functional activation controls Trypanosoma cruzi mediated maternal and placental tissue damage and improves pregnancy outcomes in mice.
Rios LE; Lokugamage N; Choudhuri S; Chowdhury IH; Garg NJ
NPJ Vaccines; 2023 Dec; 8(1):188. PubMed ID: 38104118
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
10. Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy.
Konduri V; Halpert MM; Liang D; Levitt JM; Cruz-Chan JV; Zhan B; Bottazzi ME; Hotez PJ; Jones KM; Decker WK
Infect Immun; 2017 Sep; 85(9):. PubMed ID: 28674032
[TBL] [Abstract][Full Text] [Related]
11. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells.
Limon-Flores AY; Cervera-Cetina R; Tzec-Arjona JL; Ek-Macias L; Sánchez-Burgos G; Ramirez-Sierra MJ; Cruz-Chan JV; VanWynsberghe NR; Dumonteil E
Vaccine; 2010 Oct; 28(46):7414-9. PubMed ID: 20850536
[TBL] [Abstract][Full Text] [Related]
12. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.
Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ
Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466
[TBL] [Abstract][Full Text] [Related]
13. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection.
Barry MA; Versteeg L; Wang Q; Pollet J; Zhan B; Gusovsky F; Bottazzi ME; Hotez PJ; Jones KM
PLoS Negl Trop Dis; 2019 May; 13(5):e0007413. PubMed ID: 31145733
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
[TBL] [Abstract][Full Text] [Related]
15. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
Front Immunol; 2020; 11():565142. PubMed ID: 33162979
[TBL] [Abstract][Full Text] [Related]
16. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.
Pereira IR; Vilar-Pereira G; Marques V; da Silva AA; Caetano B; Moreira OC; Machado AV; Bruna-Romero O; Rodrigues MM; Gazzinelli RT; Lannes-Vieira J
PLoS Pathog; 2015 Jan; 11(1):e1004594. PubMed ID: 25617628
[TBL] [Abstract][Full Text] [Related]
17. The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4
Jain S; George PJ; Deng W; Koussa J; Parkhouse K; Hensley SE; Jiang J; Lu J; Liu Z; Wei J; Zhan B; Bottazzi ME; Shen H; Lustigman S
Vaccine; 2018 Jun; 36(25):3650-3665. PubMed ID: 29764680
[TBL] [Abstract][Full Text] [Related]
18. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs.
Odegard JM; Flynn PA; Campbell DJ; Robbins SH; Dong L; Wang K; Ter Meulen J; Cohen JI; Koelle DM
Vaccine; 2016 Jan; 34(1):101-9. PubMed ID: 26571309
[TBL] [Abstract][Full Text] [Related]
19. An Animal Model of Acute and Chronic Chagas Disease With the Reticulotropic Y Strain of
Mateus J; Guerrero P; Lasso P; Cuervo C; González JM; Puerta CJ; Cuéllar A
Front Immunol; 2019; 10():918. PubMed ID: 31105709
[TBL] [Abstract][Full Text] [Related]
20. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
